Multiple Sclerosis Therapeutics Market
                     Multiple Sclerosis 
Therapeutics Market 
To Reach USD 25.91 
Billion By 2027
www.reportsanddata.com
Increased focus on drug discovery, accelerated delivery of new treatments for patients, 
introduction of novel and highly efficient therapies, a variety of new drugs entering the 
market, huge R&D activities & investments in multiple sclerosis (MS) therapeutics clinical 
development are key factors contributing to high CAGR of Multiple Sclerosis Therapeutics 
during forecast period.
Market Size – USD 21.29 Billion in 2018, Market Growth - CAGR of 2.5 %, Market Trends – 
Product launches and research for advanced Multiple Sclerosis Therapeutics
According to the current analysis of Reports and Data, the global Multiple Sclerosis Therapeutics 
market was valued at USD 21.29 billion in 2018 and is expected to reach USD 25.91 billion by 
year 2027, at a CAGR of 2.5 %. Multiple Sclerosis is a disabling condition of the central nervous 
system that impairs the flow of information within the brain and between the body and the brain.
www.reportsanddata.com
Market Summary
Beneficial Aspects of the Report:
The intensity of Multiple Sclerosis ranges from numbness and tingling to blindness and paralysis. Every 
person with Multiple Sclerosis has a different symptom, which makes the diagnosis difficult. Increasing 
research related to the signs and treatments related to Multiple Sclerosis is expected to drive the market 
growth. Another challenge faced by the Multiple Sclerosis therapeutics market is the lack of awareness 
among the people associated with the Multiple Sclerosis condition. The demand for Multiple Sclerosis is 
expected to increase owing to the new drug developments for treating Multiple Sclerosis. For instance, 
according to an article published on July 31, 2019, by the National MS Society, Dalfampridine tablets are 
expected to improve the information processing speed in people who have Multiple Sclerosis. Increasing 
awareness among the people in developing nations, coupled with an increase in the developments in the 
healthcare sector, is further expected to drive the market for Multiple Sclerosis therapeutics. 
www.reportsanddata.com
Market Summary
Some of the key players operating in Multiple Sclerosis Therapeutics Market  include: 
Biogen Idec, Teva Pharmaceuticals, Bayer Healthcare, Pfizer, Sanofi-Aventis, Merck, and Novartis, AbbVie 
Inc., Acorda Therapeutics Inc.
Product Type (Revenue, USD Million; 2016–2027)
Immunomodulators
Ponesimod
Glatopa
Copaxone
Avonex
Fingolimod
Teriflunomide
Others
To read more  about the report –
https://www.reportsanddata.com/report-detail/multiple-sclerosis-therapeutics-market
www.reportsanddata.com
Market Summary
Further key findings from the report suggest
Mode of Administration Type (Revenue, USD Million; 2016–2027)
Injectable
Intravenous
Oral
Related Reports – 
SB Wire  – 
http://www.sbwire.com/press-releases/multiple-sclerosis-therapeutics-market-to-reach-usd-2669-billion-by-2
027-teva-pharmaceuticals-bayer-healthcare-pfizer-sanofi-aventis-etc-1300643.htm
Globe News wire  – https://
www.globenewswire.com/news-release/2019/12/03/1955908/0/en/Multiple-Sclerosis-Therapeutics-Market-
To-Reach-USD-25-91-Billion-By-2027-Reports-And-Data.html
www.reportsanddata.com
About Us
Reports and Data is a market research and 
consulting company that provides syndicated research 
reports, customized research reports, and consulting 
services. Our solutions purely focus on your purpose to 
locate, target and analyze consumer behavior shifts 
across demographics, across industries and help client’s 
make a smarter business decision. 
Contact US
We offer market intelligence studies ensuring relevant 
and fact-based research across a multiple industries John Watson
including Healthcare, Technology, Chemicals, Power, and Head of Business Development
Energy. We consistently update our research offerings to 
ensure our clients are aware about the latest trends Reports And Data | Web: 
existent in the market. Reports and Data has a strong www.reportsanddata.com
base of experienced analysts from varied areas of Direct Line: +1-212-710-1370
expertise. E-mail: [email protected]
www.reportsanddata.com